Cue Biopharma Appoints Industry Veteran Lucinda Warren as Chief Financial and Business Officer
Rhea-AI Summary
Cue Biopharma (Nasdaq: CUE) appointed Lucinda Warren as Chief Financial and Business Officer, effective Feb 9, 2026. Ms. Warren has served as Cue’s chief business officer since Sept 2024 and brings 30+ years of global pharma and biotech experience.
Management expects Warren to help advance CUE-401, the company’s lead autoimmune asset, toward clinical development while overseeing financial and business strategy.
Positive
- CFBO appointment effective Feb 9, 2026
- Internal promotion from CBO (since Sept 2024)
- 30+ years of pharma and biotech experience
- Mandate to advance CUE-401 toward clinic
Negative
- None.
Key Figures
Market Reality Check
Peers on Argus
CUE was down 4.65% while close biotech peers showed mixed moves: ACET -5.02%, ALXO -2.93%, INKT -1.25%, but PDSB +0.15% and PYPD +0.87%. This mix points to stock-specific dynamics rather than a uniform sector trend.
Historical Context
| Date | Event | Sentiment | Move | Catalyst |
|---|---|---|---|---|
| Dec 19 | Equity offering priced | Negative | -21.6% | Pricing of ~$10M underwritten equity and warrant offering at $0.28 per unit. |
| Dec 18 | Equity offering proposed | Negative | -14.5% | Announcement of proposed underwritten stock and warrant offering with 30-day option. |
| Nov 13 | Licensing collaboration | Positive | -7.2% | Exclusive in-licensing deal for Immuno-STAT molecules in a novel solid tumor approach. |
| Nov 13 | Q3 2025 earnings | Neutral | -2.3% | Q3 results with collaboration revenue, cost shifts, cash balance and ongoing net loss. |
| Nov 06 | Strategic collaboration | Positive | -2.4% | ImmunoScape collaboration with $15M upfront and 40% equity stake plus royalties. |
Financing announcements have seen sharp, aligned sell-offs, while positive collaboration and clinical updates have often met with negative or muted price reactions.
Over the last few months, CUE has combined strategic collaborations and financings with leadership changes. A November 2025 ImmunoScape collaboration and license brought $15M upfront potential and a 40% equity stake but saw modest share declines. Q3 2025 results highlighted a 50% ORR and 88% 12‑month OS for CUE‑101 plus pembrolizumab, alongside ongoing losses and tight liquidity. December 2025 public offering announcements to raise about $10M triggered double‑digit drops, underscoring financing pressure as the company refines its leadership team, including the CFBO appointment.
Market Pulse Summary
This announcement highlights Cue Biopharma’s decision to consolidate financial and business leadership under a seasoned executive with over 30 years of sector experience, as it works to advance CUE‑401 toward the clinic. Recent history includes strategic collaborations with $15M in potential upfront cash but also dilutive offerings and going‑concern disclosures. Investors may watch how this CFBO helps navigate capital needs, pipeline milestones, and cost discipline against a backdrop of past volatility.
Key Terms
clinical-stage medical
biopharmaceutical medical
therapeutic biologics medical
t cells medical
autoimmune medical
inflammatory diseases medical
mergers and acquisitions financial
AI-generated analysis. Not financial advice.
BOSTON, Feb. 12, 2026 (GLOBE NEWSWIRE) -- Cue Biopharma, Inc. (Nasdaq: CUE), a clinical-stage biopharmaceutical company developing a novel class of therapeutic biologics to selectively engage and modulate disease-specific T cells for the treatment of autoimmune and inflammatory diseases, today announced that Lucinda Warren, who has served as Cue Biopharma’s chief business officer (CBO) since September 2024, has been appointed chief financial and business officer (CFBO) effective February 9, 2026.
“The combination of Lucinda’s financial and business acumen together with her extensive background makes the CFBO a key strategic partner in helping drive business growth and Company success, particularly as we aim to move CUE-401, our lead autoimmune asset, toward the clinic,” said Usman Azam, M.D., president and chief executive officer of Cue Biopharma.
Ms. Warren added, “I am honored to serve Cue Biopharma in this capacity, and I look forward to continuing to support the Company’s corporate priorities and to be a part of this dedicated team.”
Ms. Warren has over 30 years of global experience in the pharmaceutical and biotechnology sectors. Prior to joining Cue Biopharma, she served as vice president of business development for Neuroscience and Japan Regionally at Johnson & Johnson, a healthcare products company, from 2014 to 2024, where she was responsible for end-to-end business development, including licensing, mergers and acquisitions, and alliance management. Her leadership was instrumental in optimizing resources, fostering high-performing teams, and cultivating strong relationships with stakeholders. Ms. Warren’s extensive experience also includes significant roles at Janssen Cilag Australia and Janssen Biologics, where she led business units and managed global transitions, consistently delivering value through strategic transactions. She currently serves as chairman of the board of International School Services, contributing her expertise in finance and governance. Ms. Warren holds a B.S. in biological sciences with a minor in neurology from the University of Alberta.
About Cue Biopharma
Cue Biopharma, a clinical-stage biopharmaceutical company, is developing a novel class of injectable biologics to selectively engage and modulate disease-specific T cells directly within the patient’s body. The company’s proprietary platform, Immuno-STAT™ (Selective Targeting and Alteration of T cells) and biologics are designed to harness the curative potential of the body’s intrinsic immune system without the adverse effects of broad systemic immune modulation. CUE-401, the company’s lead autoimmune asset, is designed to act mechanistically both as a regulator of proinflammatory mechanisms, and as a master switch for regulatory T cell (Treg) differentiation to induce tolerance. It is a highly innovative, tolerogenic bifunctional molecule combining a TGF-beta breathing-mask moiety with Cue Biopharma’s clinically validated interleukin 2 (IL-2) mutein in a single injectable biologic.
Headquartered in Boston, Massachusetts, we are led by an experienced management team with deep expertise in immunology and protein engineering as well as the design and clinical development of protein biologics.
For more information please visit www.cuebiopharma.com and follow us on X and LinkedIn.
Forward-Looking Statements
This press release contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. Such forward-looking statements include, but are not limited to, those regarding: the company’s belief regarding the potential benefits and applications of its drug candidates and programs, including the company’s plans to further advance its differentiating Immuno-STAT® platform and lead autoimmune asset, CUE-401, toward the clinic; and the company’s business strategies, plans and prospects. Forward-looking statements, which are based on certain assumptions and describe the company’s future plans, strategies and expectations, can generally be identified by the use of forward-looking terms such as “believe,” “expect,” “may,” “will,” “should,” “would,” “could,” “seek,” “intend,” “plan,” “goal,” “project,” “estimate,” “anticipate,” “strategy,” “future,” “likely,” “promise” or other comparable terms, although not all forward-looking statements contain these identifying words. All statements other than statements of historical facts included in this press release regarding the company’s strategies, prospects, financial condition, operations, costs, plans and objectives are forward-looking statements. Important factors that could cause the company’s actual results and financial condition to differ materially from those indicated in the forward-looking statements include, among others, the company’s ability to maintain its collaboration with ImmunoScape; the company’s limited operating history, limited cash and a history of losses; the company’s ability to obtain adequate financing to fund its business operations in the near term and successfully remediate its current “going concern” determination that it does not have sufficient capital on hand to continue operations beyond the next twelve months; the company’s ability to achieve profitability; potential setbacks in the company’s research and development efforts including negative or inconclusive results from its preclinical studies or clinical trials or the company’s ability to replicate in later clinical trials positive results found in preclinical studies and early-stage clinical trials of its product candidates; serious and unexpected drug-related side effects or other safety issues experienced by participants in clinical trials; its ability to secure required U.S. Food and Drug Administration (“FDA”) or other governmental approvals for its product candidates and the breadth of any approved indication; adverse effects caused by public health pandemics, including possible effects on the company’s operations and clinical trials; delays and changes in regulatory requirements, policy and guidelines including potential delays in submitting required regulatory applications to the FDA; the company’s reliance on licensors, collaborators, contract research organizations, suppliers and other business partners; the company’s ability to obtain adequate financing to fund its business operations in the future and ability to continue as a going concern; the company’s ability to maintain and enforce necessary patent and other intellectual property protection; competitive factors; general economic and market conditions and the other risks and uncertainties described in the Risk Factors and Management's Discussion and Analysis of Financial Condition and Results of Operations sections of the company’s most recently filed Annual Report on Form 10-K and any subsequently filed Quarterly Report(s) on Form 10-Q. Any forward-looking statement made by the company in this press release is based only on information currently available to the company and speaks only as of the date on which it is made. The company undertakes no obligation to publicly update any forward-looking statement, whether written or oral, that may be made from time to time, whether as a result of new information, future developments or otherwise.
Investor Contact
Marie Campinell
Senior Director, Corporate Communications
Cue Biopharma, Inc.
mcampinell@cuebio.com
Media Contact
Jonathan Pappas
LifeSci Communications
jpappas@lifescicomms.com
FAQ
Who is Lucinda Warren and what role did Cue Biopharma (CUE) name her to on Feb 9, 2026?
What experience does Lucinda Warren bring to Cue Biopharma (CUE) after her Feb 2026 appointment?
How does Lucinda Warren’s appointment affect Cue Biopharma’s (CUE) plans for CUE-401?
When did Lucinda Warren join Cue Biopharma (CUE) and what was her prior internal title?
What past roles at large pharma does Cue Biopharma cite for CFBO Lucinda Warren (CUE)?
